Impact of Early Cancer Diagnosis in Healthcare System

Payel Bakshi, Sudipta Hazra, Siddhartha Chatterjee and Payel Ghosh

September 30, 2024

Impact of Early Cancer Diagnosis in Healthcare System

Payel Bakshi[1], Sudipta Hazra[2], Siddhartha Chatterjee[3] and Payel Ghosh[3]
[1]*Hospital Management, Brainware University, India*
[1]*payelbakshi22121991@gmail.com*
[2]*Computer Science and Engineering, Asansol Engineering College, India*
[2]*sudiptahazra.nitdgp@gmail.com*
[3]*Computer Science and Engineering, College of Engineering and Management Kolaghat, India*
[3]*siddhartha.chatterjee31@gmail.com*
[4]*Hospital Management, Dr. B. C. Roy Academy of Professional Courses, India*
[4]*payel.ghosh@bcrec.ac.in*

Abstract: Early cancer diagnosis plays a pivotal role in improving patient outcomes and reducing mortality rates. This research paper investigates the impact of early cancer detection on the healthcare system, examining the benefits, challenges, and implications for clinical practice. By leveraging data from various cancer registries and healthcare databases, we analyse the correlation between early diagnosis and treatment efficacy, patient survival rates, and healthcare costs. Our study reveals that early diagnosis significantly enhances the efficacy of treatment protocols, leading to higher survival rates and better quality of life for patients. Early-stage cancer detection often results in less aggressive treatments, which are not only more effective but also less costly, thereby reducing the overall burden on the healthcare system. Additionally, we explore the role of advanced diagnostic technologies, including imaging techniques and molecular diagnostics, in facilitating early detection. However, the implementation of early diagnostic strategies faces several challenges, such as accessibility, healthcare disparities, and the need for robust screening programs. The paper discusses these obstacles and suggests potential solutions to improve early cancer diagnosis rates.

***Keywords:** Cancer diagnosis, Machine learning, Healthcare.*

1. INTRODUCTION

Cancer remains one of the leading causes of morbidity and mortality worldwide, exerting a significant burden on individuals and healthcare systems. According to the World Health Organization (WHO), cancer accounts for nearly 10 million deaths annually, with projections indicating a continued rise in incidence rates. Early diagnosis of cancer is critical in improving patient outcomes, as it enables timely and appropriate treatment, which can significantly increase survival rates and enhance the quality of life. Despite advancements in cancer treatment, the stage at which cancer is diagnosed often determines the effectiveness of the treatment and the prognosis for the patient. The healthcare system benefits enormously from early cancer diagnosis. Detecting cancer at an early stage typically involves less aggressive and less expensive treatment options, thereby reducing the overall costs associated with cancer care. Moreover, early diagnosis can lead to better allocation of healthcare resources, reducing the strain on healthcare facilities and professionals. This is particularly important in resource-limited settings where healthcare resources are already stretched thin.

Advances in medical technologies and diagnostic methods, such as imaging techniques, biomarker identification, and molecular diagnostics, have significantly improved the ability to detect cancers early. Screening programs for various cancers, including breast, cervical, and colorectal cancers, have been shown to reduce mortality rates by identifying cancer in its early, more treatable stages. Despite these advancements, there remain significant challenges in implementing widespread early diagnostic strategies. These challenges include disparities in healthcare access, socioeconomic barriers, limited public awareness, and variability in the quality of diagnostic services. This research paper aims to examine the impact of early cancer diagnosis on the healthcare system by analysing its benefits, challenges, and implications. We will explore the correlation between early detection and treatment outcomes, patient survival rates, and healthcare costs. The study leverages data from various cancer registries and healthcare databases to provide a comprehensive overview of the current state of early cancer diagnosis and its effects on healthcare systems globally.

There are several areas of intersection between early cancer diagnosis and artificial intelligence (AI), two rapidly evolving fields. The UK national registry data suggests that the 1-year cancer mortality rate and the stage of cancer appear to be strongly correlated, with some subtypes facing more progressive prognostic declines with each stage [1]. When stage I sickness in lung cancer is removed, for example, the 5-year survival rates range from 70 to 90 percent; globally, these rates are currently 19% for women and 13.8% for men [2]. In 2018, 44.3% of patients in England were diagnosed with an early-stage (I or II) cancer; less than 30% of people had malignancies of the stomach, pancreas, oesophagus, oropharynx, or lung [3]. A national objective for the National Health Service (NHS) long-term plan [4] was to raise early diagnosis rates to 75% by 2028. Early detection is recognised as a crucial goal by many international institutions, including the World Health Organisation (WHO) and the International Alliance for Cancer Early Detection (ACED).

2. RELATED WORK

Several research has employed machine learning (ML) approaches in the healthcare arena to identify breast cancer in the past few years. Other scientists have applied the algorithms to difficult problems because they yield satisfactory results [5]. With an accuracy of almost 88%, a CNN algorithm was used to identify and diagnose invasive ductal carcinoma in breast cancer images [6,7]. Furthermore, it is frequently employed in the medical industry to predict and diagnose unusual events in order to gain a better knowledge of incurable illnesses like cancer [8]. Imaging and genetics-based breast cancer screening strategies have been the subject of numerous investigations. Moreover, to the best of our knowledge, no research has combined the use of these two methods. The authors of [9] provided an overview of the various methods for histological image analysis (HIA) in the detection of breast cancer. These methods are based on several kinds of convolutional neural networks (CNN) [10]. The authors categorised their work according to the type of dataset they used. Everything was arranged in reverse chronological order, starting with the most recent event. The findings of this study indicate that somewhere around the middle of 2012, ANNs were initially applied in the field of HIA. ANNs and PNNs were the most often employed types of algorithms [11].

Computational intelligence methods including fuzzy systems, artificial neural networks, and swarm intelligence, as well as evolutionary computing methods like genetic algorithms, classifiers, and support vector machines, are useful strategies in the field of smart health [12]. According to research released in 2020 [13], doctors can identify breast cancer more accurately with the help of the suggested CNN Improvements for Breast Cancer Classification (CNNI-BCC) model. The suggested method uses a trained deep learning (DL) neural network system to classify subtypes of breast cancer. With data from 221 actual patients, the accuracy percentage of the outcomes is 90.50 percent. This model is capable of classifying and identifying breast cancer lesions without the requirement for human interaction. An evaluation of this model demonstrates that it is an improvement over previous methodologies (Tanabe, Ikeda et al., 2020) [14] by being able to examine the situation of afflicted patients during the detecting period. [15] carried out a comparison to find the similarities and differences between SVM, logistic regression, naive Bayes, and random forest. The Wisconsin breast cancer dataset is used as a point of reference [16]. The random forest algorithm produced the greatest accuracy (99.76%) with the least amount of error, according to the evaluation findings. Each experiment was conducted in a repeatable setting using the Anaconda Data Science Platforms [17]. The authors suggested a method for classifying breast cancer into several categories.

3. OVERVIEW OF AI IN ONCOLOGY

AI is a catch-all phrase for computers that simulate human intelligence. Under AI, ML is the process of train the computer various algorithms to make predictions based on past performance. ML may be generally classified into two categories: supervised learning, which allows the computer to see outcome data, and unsupervised learning, which does not offer end data. Both methodologies look for patterns in the data to predict outcomes, such as the presence or absence of cancer, survival rates, or risk groups. Natural language processing (NLP) is a technique that is frequently used in cancer and other fields to analyse unstructured clinical data [5]. NLP converts unstructured free-text into a format that can be analysed by computers, which makes resource-intensive jobs automatable. Within ML, DL is a subfield that builds complex architectures that resemble the linked neurons found in the human brain. Tensorflow (Google) and PyTorch (Facebook) are two well-known Python-based DL frameworks that offer tools for model creation, training, and assessment. Additionally, Google offers a free online notebook environment called Google Colaboratory that enables access to GPUs and cloud-based Python programming without the need to install anything locally.

Artificial neural networks (ANNs) can be used to illustrate the general ideas, albeit a thorough discussion of neural network architectures is outside the purview of this article (Figure 1). Muhammad et al., for instance, employed an ANN to predict the risk of pancreatic cancer based on clinical characteristics such age, ethnicity, smoking status, and alcohol consumption [11]. An input layer, a "hidden layer," made up of several nodes that multiply the input by weights and add a bias value, and an output layer that sends the weighted sum of the hidden layer nodes to an activation function for prediction are the three main components of an artificial neural network (ANN). The term "deep learning" essentially describes networks that have multiple hidden layers.



Fig.1. ANN architecture with a single hidden layer as an example.

Convolutional neural network (CNN) architectures, which made it possible to employ colour photographs as input data, revolutionised computer-vision research and were used in many early diagnosis models. Although the downstream fully connected layers are similar to those of an artificial neural network (ANN), a number of kernels handle the input data by slicing over the colour channels of the image and extracting features like edges and colour gradients. Prior to being sent to the fully linked layer, these inputs are subsequently combined and flattened. CNNs are quite useful in digital pathology and radiology, as we will see later in this essay.

Numerous new modalities of healthcare data can be analysed with AI. The proliferation of electronic healthcare record (EHR) infrastructures worldwide in recent years has made it possible to store and retrieve large amounts of clinical data in an efficient manner [16]. The UK-wide DATA-CAN centre is one of the many innovative digital collaborations that are emerging to support early diagnosis research using EHRs [17]. Data on pathways and outcome measures are kept in other digital databases. For example, the Digital Cancer Waiting Times Database aims to improve cancer referral paths by using user-uploaded performance indicators [18]. Differentiating between national public health data registries, which include those used in multi-center screening studies, and local hospital EHR data is crucial. To ensure uniformity throughout institutions, registers are being used to create unified database architecture. Ensuring system interoperability is a major goal of the NHSx "digital transformation of screening" initiative, which aims to allow data to flow effortlessly along the whole screening process, including into national registration databases [19]. The new U.K. cervical cancer screening management system, which will consolidate 84 disparate databases into a single national database with the goal of streamlining data entry and offering consumers easy, cloud-based access, is an example of database unification [20].

This involves classifying ambiguous nodules or cysts as benign or malignant in the context of early cancer diagnosis. This method of effectively classifying lung nodules has been used in numerous research [21, 22]. Shakir et al. have produced accurate radiomics-based cancer likelihood functions across a variety of tumour types, including colorectal, lung, and head and neck cancers [23]. Predicting indolence vs aggressive disease is another possibility; this can help determine when an early diagnosis is most likely to assist a patient. For instance, a four-feature radiomics signature that predicted ovarian cancer survival and treatment response was published by Lu et al. in 2019 [24]. With automated whole-slide analysis, CNNs have been widely used for cancer detection: a model developed by Coudray et al. identified lung cancer with an AUC of 0.97 [25], and good diagnosis accuracy has been noted for additional tumour subtypes [26]. CNNs have been trained to automate grade and stage evaluations [27], and they can undertake tumour sub-typing, which includes identifying molecular phenotypes and targetable receptors [28]. Utilising a CNN model in this instance, applications like Paige-AI may offer clinically accessible instruments for automated examination of prostate biopsies [29].

4. CLINICAL APPLICATIONS

Numerous extensive studies have demonstrated the benefits of lung cancer screening for at-risk individuals in terms of survival [30]. Following this, the Centres for Medicare & Medicaid Services (CMS) in the United States determined that individuals between the ages of 55 and 77 who had a smoking history of ≥30 pack years were eligible for CT screening; however, revised guidelines recommend that this should be further lowered [31]. Unfortunately, due in part to inadequate documentation of smoking status and physician time constraints, only a tiny percentage of eligible patients are actually screened in practice [32]. Many decision-support systems have been developed in the past ten years to help general practitioners (GPs) decide whether cancer symptoms call for a referral for additional testing [33]. To help GPs with cancer risk stratification, for instance, a number of practices are presently piloting 'C The Signs,' a CE-marked decision support tool [34]. Based on cancer symptom profiles, the programme offers a dashboard for real-time use and recommends investigations or referrals. An elevated cancer detection rate of 6.4% is shown by early evaluation reports [35].



Fig.2. Clinical applications of AI in early cancer diagnosis.

The group created a manual review priority system based on a mix of the type of discoveries (positive or negative) and model confidence, and trained a range of CNN architectures to perform Cytosponge slide quality control and BE detection [36]. The selected CNN could fully automate five of the eight diagnosis-confidence categories with diagnostic accuracy comparable to that of a pathologist (sensitivity and specificity, 82.5% and 92.7%, respectively). The approach demonstrated a simulated reduction in pathologist effort of 57.2% when tested externally on 3038 slides from 1519 patients [36]. An end-to-end solution, which combined nodule identification and classification into a single workstream and was trained using 42,290 CT scans from 14,851 patients participating in the National Lung Screening Trial, was reported by Ardila and co-authors at Google [52,80]. Whole-CT scan data and bounding-box nodule ROIs were then used in conjunction with a 3D Inception model to predict malignancy [52]. The model attained a state-of-the-art AUC of 95.5% at external validation in 1139 cases, outperforming the average radiologist in malignancy risk-prediction [37]. Although the model hasn't been prospectively tested, it might eventually be made available for clinical use.

More encouraging advancements in cancer are early detection of recurrence following treatment and improved prognostication. Pre-treatment accurate prognostication may allow for tailored therapy, with lower-risk patients categorised to less intensive treatment to minimise side effects, and high-risk cases offered more intensive primary treatment, such as increasing the dose of radiation therapy [38]. A widely recommended component of cancer care is post-treatment monitoring, which provides patients with continuous assistance for side effects related to their therapy, assurance, and co-morbidity management. Hepatocellular carcinoma (HCC), bladder, melanoma, and rectal tumours are among the diseases for which digital pathology has showed potential in ML-based recurrence prediction [39]. After surgically removing HCC, Yamashita et al. created a DL model for recurrence risk that outperformed TNM-based prognostication [40]. With statistically significant variations in survival, the model successfully categorised patients into low- and high-risk groups [40]. In locally excised rectal cancer, Jones et al. found that the ratio of desmoplastic to inflammatory stroma predicts disease recurrence.

5. CHALLENGES

Healthcare AI has a lot of promise, but it also comes with a lot of challenges, including data bias, algorithmic fairness, governance, and security concerns. The development of ethical norms and standards is a major area of continuous attention in healthcare AI. The WHO has called on stakeholders in healthcare AI to ensure that human rights and ethics are given top priority in the development and implementation of new technologies. Common worries have already been covered, including the influence on collaborative decision-making and patient experience, the black-box nature of AI judgements, and accountability in the event that AI is unable to produce correct predictions. A detailed examination of ethical concerns is outside the scope of this review. Numerous AI systems for breast cancer screening were found to have poor methodological quality in a recent comprehensive review, and promising outcomes from small studies did not translate to larger trials. Ultimately, an excessive number of retrospective models lack external validation, which also results in too optimistic performance estimates [41-45]. The high quality of generalizability evidence needed for clinical adoption is lacking in models without external validation.

6. CONCLUSION

This analysis includes a number of CNN models that have been shown to impact workflow triage. These algorithms are able to recognise early-stage cancers on scan or biopsy images with high accuracy. Many commercial choices are currently available for automated cancer detection, and utilisation of these solutions may increase in the future years. In the context of symptomatic patient decision-support, we argue, caution must be taken to ensure that models are validated and published in peer-reviewed papers before being used. Furthermore, we discovered that there are other barriers to the application of AI, including the costly and time-consuming nature of data anonymization and storage for healthcare institutions. We also talked about model bias and how it affects generalizability, particularly how important demographic information like race and ethnicity is underreported. In order to improve study quality and model uptake in the future, quality assurance frameworks (such as SPIRIT-AI) and methods to standardise radiomic feature values across institutions—as recommended by the image biomarker standardisation initiative- may be useful [34]. Furthermore, "gold standard" test sets tailored to a particular condition could make it easier for clinicians to benchmark rival models. Notwithstanding the aforementioned difficulties, AI has extremely promising potential for early cancer diagnosis, and the field is expected to expand quickly in the years to come.

REFERENCES

[1] McPhail S., Johnson S., Greenberg D., Peake M., Rous B. Stage at diagnosis and early mortality from cancer in England. Br. J. Cancer. 2015;112:S108–S115.

[2] Knight S.B., Crosbie P.A., Balata H., Chudziak J., Hussell T., Dive C. Progress and prospects of early detection in lung cancer. Open Biol. 2017;7:170070.

[3] Hazra, S., Ghosal, S., Mondal, A., Dey, P. (2024). Forecasting of Rainfall in Subdivisions of India Using Machine Learning. In: Bhattacharyya, S., Das, G., De, S., Mrsic, L. (eds) Recent Trends in Intelligence Enabled Research. DoSIER 2023. Advances in Intelligent Systems and Computing, vol 1457. Springer, Singapore. https://doi.org/10.1007/978-981-97-2321-8_18

[4] Gon, Anudeepa, Sudipta Hazra, Siddhartha Chatterjee, and Anup Kumar Ghosh. "Application of Machine Learning Algorithms for Automatic Detection of Risk in Heart Disease." In *Cognitive Cardiac Rehabilitation Using IoT and AI Tools*, pp. 166-188. IGI Global, 2023.

[5] Yim W., Yetisgen M., Harris W.P., Kwan S.W. Natural Language Processing in Oncology: A Review. JAMA Oncol. 2016;2:797–804. doi: 10.1001/jamaoncol.2016.0213.

[6] Chhatwal J., Alagoz O., Lindstrom M.J., Kahn C.E., Shaffer K.A., Burnside E.S. A logistic regression model based on the national mammography database format to aid breast cancer diagnosis. Am. J. Roentgenol. 2009;192:1117–1127. doi: 10.2214/AJR.07.3345.

[7] Zhang F., Kaufman H.L., Deng Y., Drabier R. Recursive SVM biomarker selection for early detection of breast cancer in peripheral blood. BMC Med. Genom. 2013;6((Suppl. 1)):S4. doi: 10.1186/1755-8794-6-S1-S4.

[8] Olatunji S.O., Alotaibi S., Almutairi E., Alrabae Z., Almajid Y., Altabee R., Altassan M., Basheer Ahmed M.I., Farooqui M., Alhiyafi J. Early diagnosis of thyroid cancer diseases using computational intelligence techniques: A case study of a Saudi Arabian dataset. Comput. Biol. Med. 2021;131:104267. doi: 10.1016/j.compbiomed.2021.104267.

[9] Xiao L.H., Chen P.R., Gou Z.P., Li Y.Z., Li M., Xiang L.C., Feng P. Prostate cancer prediction using the random forest algorithm that takes into account transrectal ultrasound findings, age, and serum levels of prostate-specific antigen. Asian J. Androl. 2017;19:586. doi: 10.4103/1008-682X.186884. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

[10] Liew X.Y., Hameed N., Clos J. An investigation of XGBoost-based algorithm for breast cancer classification. Mach. Learn. Appl. 2021;6:100154. doi: 10.1016/j.mlwa.2021.100154.

[11] Muhammad W., Hart G.R., Nartowt B., Farrell J.J., Johung K., Liang Y., Deng J. Pancreatic Cancer Prediction Through an Artificial Neural Network. Front. Artif. Intell. 2019;2:2. doi: 10.3389/frai.2019.00002.

[12] Szegedy C., Liu W., Jia Y., Sermanet P., Reed S., Anguelov D., Erhan D., Vanhoucke V., Rabinovich A. Going deeper with convolutions; Proceedings of the IEEE Computer Society Conference on Computer Vision and Pattern Recognition; Boston, MA, USA. 7–12 June 2015; pp. 1–9.

[13] Tan M., Le Q.V. EfficientNet: Rethinking Model Scaling for Convolutional Neural Networks; Proceedings of the 36th International Conference on Machine Learning, ICML 2019; Long Beach, CA, USA. 9–15 June 2019; pp. 10691–10700.

[14] He K., Zhang X., Ren S., Sun J. Deep residual learning for image recognition; Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition; Las Vegas, NV, USA. 27–30 June 2016; pp. 770–778.

[15] Huang G., Liu Z., Van Der Maaten L., Weinberger K.Q. Densely Connected Convolutional Networks; Proceedings of the 30th IEEE Conference on Computer Vision and Pattern Recognition CVPR 2017; Honolulu, HI, USA. 21–26 July 2016; pp. 2261–2269. [CrossRef] [Google Scholar]

[16] Gillum R.F. From papyrus to the electronic tablet: A brief history of the clinical medical record with lessons for the digital age. Am. J. Med. 2013;126:853–857. doi: 10.1016/j.amjmed.2013.03.024.

[17] DATA-CAN: Health Data Research Hub for Cancer|UCLPartners. [(accessed on 18 October 2021)]. Available online: https://uclpartners.com/work/data-can-health-data-research-hub-cancer/

[18] Hazra, Sudipta, Swagata Mahapatra, Siddhartha Chatterjee, and Dipanwita Pal. "Automated Risk Prediction of Liver Disorders Using Machine Learning." In *the proceedings of 1st International conference on Latest Trends on Applied Science, Management, Humanities and Information Technology (SAICON-IC-LTASMHIT-2023) on 19th June*, pp. 301-306. 2023.

[19] Banerjee, S., Hazra, S., Kumar, B. (2023). Application of Big Data in Banking—A Predictive Analysis on Bank Loans. In: Peng, SL., Jhanjhi, N.Z., Pal, S., Amsaad, F. (eds) Proceedings of 3rd International Conference on Mathematical Modeling and Computational Science. ICMMCS 2023. Advances in Intelligent Systems and Computing, vol 1450. Springer, Singapore. https://doi.org/10.1007/978-981-99-3611-3_40

[20] Hazra, S., Chatterjee, S., Mandal, A., Sarkar, M., Mandal, B.K. (2023). An Analysis of Duckworth-Lewis-Stern Method in the Context of Interrupted Limited over Cricket Matches. In: Chaki, N., Roy, N.D., Debnath, P., Saeed, K. (eds) Proceedings of International Conference on Data Analytics and Insights, ICDAI 2023. ICDAI 2023. Lecture Notes in Networks and Systems, vol 727. Springer, Singapore. https://doi.org/10.1007/978-981-99-3878-0_46

[21] Chen X., Feng B., Chen Y., Liu K., Li K., Duan X., Hao Y., Cui E., Liu Z., Zhang C., et al. A CT-based radiomics nomogram for prediction of lung adenocarcinomas and granulomatous lesions in patient with solitary sub-centimeter solid nodules. Cancer Imaging. 2020;20:1–13.

[22] Beig N., Khorrami M., Alilou M., Prasanna P., Braman N., Orooji M., Rakshit S., Bera K., Rajiah P., Ginsberg J., et al. Perinodular and Intranodular Radiomic Features on Lung CT Images Distinguish Adenocarcinomas from Granulomas. Radiology.2019;290:783–792.doi: 10.1148/radiol.2018180910.

[23] Shakir H., Deng Y., Rasheed H., Khan T.M.R. Radiomics based likelihood functions for cancer diagnosis. Sci. Rep. 2019;9:9501. doi: 10.1038/s41598-019-45053-x.

[24] Lu H., Arshad M., Thornton A., Avesani G., Cunnea P., Curry E., Kanavati F., Liang J., Nixon K., Williams S.T., et al. A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nat. Commun. 2019;10:764. doi: 10.1038/s41467-019-08718-9.

[25] Coudray N., Ocampo P.S., Sakellaropoulos T., Narula N., Snuderl M., Fenyö D., Moreira A.L., Razavian N., Tsirigos A. Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning. Nat. Med. 2018;24:1559–1567. doi: 10.1038/s41591-018-0177-5.

[26] Sui D., Liu W., Chen J., Zhao C., Ma X., Guo M., Tian Z. A Pyramid Architecture-Based Deep Learning Framework for Breast Cancer Detection. Biomed Res. Int. 2021;2021:1–10. doi: 10.1155/2021/2567202.

[27] Ström P., Kartasalo K., Olsson H., Solorzano L., Delahunt B., Berney D.M., Bostwick D.G., Evans A.J., Grignon D.J., Humphrey P.A., et al. Artificial intelligence for diagnosis and grading of prostate cancer in biopsies: A population-based, diagnostic study. Lancet Oncol. 2020;21:222–232. doi: 10.1016/S1470-2045(19)30738-7.

[28] Naik N., Madani A., Esteva A., Keskar N.S., Press M.F., Ruderman D., Agus D.B., Socher R. Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains. Nat. Commun. 2020;11:5727. doi: 10.1038/s41467-020-19334-3.

[29] da Silva L.M., Pereira E.M., Salles P.G.O., Godrich R., Ceballos R., Kunz J.D., Casson A., Viret J., Chandarlapaty S., Ferreira C.G., et al. Independent real-world application of a clinical-grade automated prostate cancer detection system. *J. Pathol.* 2021;254:147–158.

[30] Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., Gareen I.F., Gatsonis C., Marcus P.M., Sicks J.R.D. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. N. Engl. J. Med. 2011;365:395–409. doi: 10.1056/nejmoa1102873.

[31] Dyer O. US task force recommends extending lung cancer screenings to over 50s. BMJ. 2021;372:n698. doi: 10.1136/bmj.n698.

[32] Richards T.B., Doria-Rose V.P., Soman A., Klabunde C.N., Caraballo R.S., Gray S.C., Houston K.A., White M.C. Lung Cancer Screening Inconsistent With U.S. Preventive Services Task Force Recommendations. *Am. J. Prev. Med.* 2019;56:66–73. doi: 10.1016/j.amepre.2018.07.030.

[33] Hamilton W., Green T., Martins T., Elliott K., Rubin G., Macleod U. Evaluation of risk assessment tools for suspected cancer in general practice: A cohort study. *Br. J. Gen. Pract.* 2013;63:e30. doi: 10.3399/bjgp13X660751.

[34] Zwanenburg A., Vallières M., Abdalah M.A., Aerts H.J.W.L., Andrearczyk V., Apte A., Ashrafinia S., Bakas S., Beukinga R.J., Boellaard R., et al. The image biomarker standardization initiative: Standardized quantitative radiomics for high-throughput image-based phenotyping. *Radiology.* 2020;295:328–338.

[35] Shaheen N.J., Falk G.W., Iyer P.G., Gerson L.B. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. *Am. J. Gastroenterol.* 2016;111:30–50. doi: 10.1038/ajg.2015.322.

[36] Gehrung M., Crispin-Ortuzar M., Berman A.G., O'Donovan M., Fitzgerald R.C., Markowetz F. Triage-driven diagnosis of Barrett's esophagus for early detection of esophageal adenocarcinoma using deep learning. *Nat. Med.* 2021;27:833–841. doi: 10.1038/s41591-021-01287-9.

[37] Ardila D., Kiraly A.P., Bharadwaj S., Choi B., Reicher J.J., Peng L., Tse D., Etemadi M., Ye W., Corrado G., et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. *Nat. Med.* 2019;25:954–961. doi: 10.1038/s41591-019-0447-x.

[38] Rezaeijo S.M., Hashemi B., Mofid B., Bakhshandeh M., Mahdavi A., Hashemi M.S. The feasibility of a dose painting procedure to treat prostate cancer based on mpMR images and hierarchical clustering. *Radiat. Oncol.* 2021;16:182. doi: 10.1186/s13014-021-01906-2.

[39] Kulkarni P.M., Robinson E.J., Pradhan J.S., Gartrell-Corrado R.D., Rohr B.R., Trager M.H., Geskin L.J., Kluger H.M., Wong P.F., Acs B., et al. Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death. *Clin. Cancer Res.* 2020;26:1126–1134. doi: 10.1158/1078-0432.CCR-19-1495.

[40] Yamashita R., Long J., Saleem A., Rubin D.L., Shen J. Deep learning predicts postsurgical recurrence of hepatocellular carcinoma from digital histopathologic images. *Sci. Rep.* 2021;11:2047. doi: 10.1038/s41598-021-81506-y.

[41] Sima Das, Siddhartha Chatterjee, Sutapa Bhattacharya, Solanki Mitra, Arpan Adhikary and Nimai Chandra Giri "Movie's-Emotracker: Movie Induced Emotion Detection by using EEG and AI Tools", In the proceedings of the 4th International conference on Communication, Devices and Computing (ICCDC 2023), Springer-LNEE SCOPUS Indexed, DOI: 10.1007/978-981-99-2710-4_46, pp.583-595, vol. 1046 on 28th July, 2023.

[42] Payel Ghosh, Sudipta Hazra and Siddhartha Chatterjee, "Future Prospects Analysis in Healthcare Management Using Machine Learning Algorithms" In the International Journal of Engineering and Science Invention (IJESI), ISSN (online): 2319-6734, ISSN (print): 2319-6726, Vol.12, Issue 6, pp. 52-56, Impact Factor – 5.962, UGC Sl. No.- 2573, Journal No.- 43302, DOI: 10.35629/6734-12065256, June 17, 2023.

[43] Soumen Das, Siddhartha Chatterjee, Debasree Sarkar and Soumi Dutta, "Comparison Based Analysis and Prediction for Earlier Detection of Breast Cancer Using Different Supervised ML Approach" In Emerging Technologies in Data Mining and Information security (IEMIS 2022), Advances in Intelligent Systems and Computing (AISC, volume 1348, pp 255 – 267 on 30 September 2022,http://doi.org/10.1007/978-981-19-4193-9 (Springer).

[44] Ghosh, P., Dutta, R., Agarwal, N., Chatterjee, S., & Mitra, S. (2023). Social media sentiment analysis on third booster dosage for COVID-19 vaccination: a holistic machine learning approach. *Intelligent Systems and Human Machine Collaboration: Select Proceedings of ICISHMC 2022*, 179-190.

[45] Sudipta Hazra, Surjyasikha Das, Rituparna Mondal, Prerona Sanyal, Anwesa Naskar, Pratiksha Hazra, Kuntal Bose, Shirsha Mullick, Swarnakshi Ghosh and Siddhartha Chatterjee "Pervasive Nature of AI in the Health Care Industry: High-Performance Medicine", In International Journal of Research and Analysis in Science and Engineering (IJRASE), Peer Reviewed UGC Sponsored, ISSN: 2582-8118, Vol. 4, Issue. 1, pp. 1-16 on 10th January, 2024.